| Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis CD Fell, FJ Martinez, LX Liu, S Murray, MLK Han, EA Kazerooni, ... American journal of respiratory and critical care medicine 181 (8), 832-837, 2010 | 276 | 2010 |
| Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis J Morisset, KA Johannson, E Vittinghoff, C Aravena, BM Elicker, KD Jones, ... Chest 151 (3), 619-625, 2017 | 235 | 2017 |
| Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada RB Hopkins, N Burke, C Fell, G Dion, M Kolb European Respiratory Journal 48 (1), 187-195, 2016 | 185 | 2016 |
| Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials LA Saketkoo, S Mittoo, D Huscher, D Khanna, PF Dellaripa, O Distler, ... Thorax 69 (5), 436-444, 2014 | 134 | 2014 |
| The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis CD Fell, LX Liu, C Motika, EA Kazerooni, BH Gross, WD Travis, TV Colby, ... American journal of respiratory and critical care medicine 179 (5), 402-407, 2009 | 131 | 2009 |
| Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis KR Flaherty, CD Fell, JT Huggins, H Nunes, R Sussman, C Valenzuela, ... European Respiratory Journal 52 (2), 2018 | 121 | 2018 |
| Sex differences in physiological progression of idiopathic pulmonary fibrosis MK Han, S Murray, CD Fell, KR Flaherty, GB Toews, J Myers, TV Colby, ... European Respiratory Journal 31 (6), 1183-1188, 2008 | 116 | 2008 |
| Pulmonary manifestations of systemic lupus erythematosus S Mittoo, CD Fell Seminars in respiratory and critical care medicine 35 (02), 249-254, 2014 | 108 | 2014 |
| BTS Clinical Statement on pulmonary sarcoidosis M Thillai, CP Atkins, A Crawshaw, SP Hart, LP Ho, V Kouranos, ... Thorax 76 (1), 4-20, 2021 | 106 | 2021 |
| Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled … JJ Solomon, SK Danoff, FA Woodhead, S Hurwitz, R Maurer, I Glaspole, ... The Lancet Respiratory Medicine 11 (1), 87-96, 2023 | 77 | 2023 |
| Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry N Hambly, MM Farooqi, A Dvorkin-Gheva, K Donohoe, K Garlick, ... European Respiratory Journal 60 (4), 2022 | 69 | 2022 |
| Idiopathic pulmonary fibrosis: phenotypes and comorbidities CD Fell Clinics in chest medicine 33 (1), 51-57, 2012 | 66 | 2012 |
| Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis JH Fisher, M Kolb, M Algamdi, J Morisset, KA Johannson, S Shapera, ... BMC pulmonary medicine 19, 1-9, 2019 | 64 | 2019 |
| The Canadian Registry for Pulmonary Fibrosis: design and rationale of a national pulmonary fibrosis registry CJ Ryerson, B Tan, CD Fell, H Manganas, S Shapera, S Mittoo, ... Canadian respiratory journal 2016, 2016 | 60 | 2016 |
| Annual risk of tuberculosis infection in rural China: a population-based prospective study L Gao, L Bai, J Liu, W Lu, X Wang, X Li, J Du, X Chen, H Zhang, H Xin, ... European Respiratory Journal 48 (1), 168-178, 2016 | 46 | 2016 |
| Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease–related interstitial lung … LA Saketkoo, S Mittoo, S Frankel, D LeSage, C Sarver, K Phillips, ... The Journal of rheumatology 41 (4), 792-798, 2014 | 46 | 2014 |
| Smoking-related idiopathic interstitial pneumonia KR Flaherty, C Fell, MC Aubry, K Brown, T Colby, U Costabel, TJ Franks, ... European Respiratory Journal 44 (3), 594-602, 2014 | 45 | 2014 |
| Supplemental oxygen in interstitial lung disease: an art in need of science KA Johannson, SR Pendharkar, K Mathison, CD Fell, JA Guenette, ... Annals of the American Thoracic Society 14 (9), 1373-1377, 2017 | 40 | 2017 |
| High oxygen delivery to preserve exercise capacity in patients with idiopathic pulmonary fibrosis treated with nintedanib. Methodology of the HOPE-IPF study CJ Ryerson, PG Camp, ND Eves, M Schaeffer, N Syed, S Dhillon, ... Annals of the American Thoracic Society 13 (9), 1640-1647, 2016 | 40 | 2016 |
| Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease APY Tsai, S Am Hur, A Wong, M Safavi, D Assayag, KA Johannson, ... Thorax 76 (1), 37-43, 2021 | 33 | 2021 |
